Landscape of Immune-Related Markers and Potential Therapeutic Targets in Soft Tissue Sarcoma.
TCGA
immune checkpoint
immunotherapy
mutational burden
next-generation sequencing
soft tissue sarcoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
19 Oct 2021
19 Oct 2021
Historique:
received:
07
09
2021
revised:
13
10
2021
accepted:
17
10
2021
entrez:
23
10
2021
pubmed:
24
10
2021
medline:
24
10
2021
Statut:
epublish
Résumé
Soft tissue sarcomas, depending on the subtype and grade, frequently recur and become metastatic after localized treatment. There is now great interest in applying immunotherapy to sarcomas to immuno-profile the different subtypes and immune monitor for prognosis. Our group previously showed that key immunotherapy target genes are present in sarcomas. Here, we extend our findings by demonstrating that sarcomas with a relatively high mutational load are likely to be more sensitive to immunotherapy compared to sarcomas with a lower mutation load. We also show that sarcomas with a higher mutation load are associated with the expression of key immune-related genes. We found that CD8+ T cells are present in sarcoma subtypes and that
Identifiants
pubmed: 34680396
pii: cancers13205249
doi: 10.3390/cancers13205249
pmc: PMC8534178
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : American Cancer Society
ID : Postdoctoral Fellowship 131779-PF-18-034-01-DMC
Références
Oncologist. 2020 Jan;25(1):e147-e159
pubmed: 31578273
Crit Rev Oncol Hematol. 2018 Jun;126:1-5
pubmed: 29759550
Lancet Oncol. 2017 Nov;18(11):1493-1501
pubmed: 28988646
Cancer Cell. 2018 Apr 9;33(4):676-689.e3
pubmed: 29622463
Hum Pathol. 2015 Mar;46(3):357-65
pubmed: 25540867
Mod Pathol. 2019 Dec;32(12):1772-1785
pubmed: 31263176
Nat Rev Clin Oncol. 2014 Apr;11(4):187-202
pubmed: 24642677
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Cancers (Basel). 2019 Aug 31;11(9):
pubmed: 31480474
Cancers (Basel). 2021 Aug 01;13(15):
pubmed: 34359785
J Glob Oncol. 2018 Sep;4:1-6
pubmed: 30241159
Cancers (Basel). 2019 May 15;11(5):
pubmed: 31096717
J Immunother Cancer. 2017 Dec 19;5(1):101
pubmed: 29254508
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514
pubmed: 32442275
Nat Commun. 2020 Feb 19;11(1):951
pubmed: 32075964
EMBO Mol Med. 2020 Nov 6;12(11):e11131
pubmed: 33047515
Science. 2017 Jan 20;355(6322):
pubmed: 28104840
Hum Vaccin Immunother. 2017 May 4;13(5):1105-1108
pubmed: 28121247
Cell. 2017 Nov 2;171(4):950-965.e28
pubmed: 29100075
Cancer. 2017 Sep 1;123(17):3291-3304
pubmed: 28463396
Clin Cancer Res. 2021 Mar 1;27(5):1236-1241
pubmed: 33199494
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32792357
Oncoimmunology. 2017 Jan 27;6(3):e1279777
pubmed: 28405504
Clin Transl Oncol. 2021 Aug;23(8):1620-1629
pubmed: 33635466
J Immunother Cancer. 2021 Feb;9(2):
pubmed: 33526607
Curr Oncol. 2020 Feb;27(Suppl 1):17-23
pubmed: 32174754
CA Cancer J Clin. 2020 May;70(3):200-229
pubmed: 32275330
Med Mol Morphol. 2019 Mar;52(1):44-51
pubmed: 29980952
Clin Sarcoma Res. 2017 Jun 15;7:11
pubmed: 28630682